World Diabetes Market Analysis, 2009-2023

Published by: Visiongain

Published: Feb. 10, 2009 - 121 Pages

Table of Contents

1 EXECUTIVE SUMMARY

1.1 Crucial Details of the Diabetes Market Trajectory

1.1.1 Visiongain Predicts the Diabetes Market will approach $64 billion by 2023

1.1.2 Diabetes is Spreading at an Epidemic Rate: The Need for Pharmaceuticals

is Growing

1.1.3 Diabetes Care Works: The Market Will Expand Significantly

1.1.4 Awareness, Advocacy, and Government Spending aimed at Diabetes are all

Expanding

1.2 Aims, Scope and Format of the Report

1.3 Research Methodology

2 INTRODUCTION

2.1 What is Diabetes Mellitus?

2.1.1 Symptoms of Diabetes

2.1.2 Type 1 Diabetes

2.1.3 Type 2 Diabetes

2.1.4 Gestational Diabetes

2.1.5 Other types of Diabetes

2.1.6 “Pre-Diabetes”: Impaired Glucose Tolerance (IGT) and Metabolic

Syndrome

2.2 Health Consequences: Diabetes Can Cause Heart, Kidney, Eye, and Nerve Damage

2.3 Obesity: The Major Diabetes Risk Factor

2.4 Other Risk Factors: Age, Genetics, Race

2.5 Diagnosis: Guidelines are Subject to Change

2.6 Prevalence: By All Measures, Diabetes Rates are Rising Epidemically

2.7 The Economic Costs of Diabetes: $58 billion in the US, $41 billion in Africa

2.8 Treatments

2.8.1 Insulin: A Central Therapeutic Product

2.8.1.1 Crucial Insulin Characteristics: Onset, Peak, and Duration Modifications

2.8.1.2 Invasive Insulin Delivery Methods: Injections, Pumps, Insulin Jets

2.8.1.3 Moving Away from Injections? Alternative Delivery Methods Under

Development, and Set to Revolutionize the Market

2.8.2 Medications

2.8.3 More Novel Therapies? A New Discovery about How Insulin Works May

Lead to New Drugs

2.9 Diabetes Treatment Noncompliance Rates 25% to 90%

3 WORLD DIABETES MARKET, 2008-2023

3.1 Market Forecast, 2008-2023

3.2 Leading Drugs

3.2.1 Byetta: Potentially Revolutionary Blockbuster

3.2.2 Oral Antidiabetics Forecast

3.2.3 Actos

3.2.4 Avandia: Unlikely to Survive past 2013

3.2.5 Januvia

3.2.6 Avandamet

3.2.7 Human Insulin and Analogues Forecast

3.2.8 Lantus

3.2.9 Novorapid

3.2.10 Humalog

3.2.11 Novomix

3.2.12 Actraphane HM

3.2.13 Levemir

3.2.14 Other Diabetes-related Drugs: Symlin Up and Kinedak Down

3.3 Alternative Delivery Methods: The Possibilities to Watch

4 LEADING COMPANIES

4.1 Novo Nordisk

4.2 Takeda

4.3 Sanofi-aventis

4.4 Eli Lilly

4.5 Amylin

4.6 Pipeline Developments

4.6.1 Liraglutide

4.6.2 Other GLP-1 Analogues

4.6.3 DPP-4 Inhibitors

4.6.4 Biguanides

4.6.5 New Therapy Class: Sodium-glucose cotransporter-2 (SGLT2) inhibitors

4.6.6 Insulin Pipelines: Some New Insulins, but Mostly Focused On Delivery

Methods

4.6.7 Pipeline for a Cure?

5 WORLD MARKET ANALYSIS BY REGION

5.1 United States

5.2 Europe

5.3 Japan

5.4 India: Becoming the Largest World Market?

5.5 China: Another Region to Watch Closely

5.6 The Rest of the World

6 SWOT (STRENGTHS, WEAKNESSES, OPPORTUNITIES, THREATS) ANALYSIS

6.1 Strengths: Diabetes is Increasing, and Diabetes Drugs Work

6.2 Weaknesses

6.3 Opportunities

6.4 Threats

6.4.1 The Most Significant Threat: Potential Changes in Drug Approval

Guidelines

6.4.2 Other Significant Threats

6.5 Interview with Fred Levine, M.D., Ph.D. Professor, Burnham Institute for Medical

Research; Director, Sanford Children’s Health Research Center

6.5.1 On alternative delivery methods:

6.5.2 On cardiovascular problems associated with oral antidiabetics

6.5.3 On obesity and diabetes

6.5.4 On Byetta

6.5.5 On Stem Cell Therapy/Cure

6.6 Interview with Björn Tyrberg, PhD. Associate Professor at Burnham Institute for

Medical Research, Diabetes and Obesity Research Center.

6.6.1 On Diet and Diabetes

6.6.2 On Byetta and liraglutide

7 CONCLUSIONS: DIABETES IS A GROWTH MARKET

Abstract

• Analyses of the strengths, weaknesses, opportunities and threats that will affect the global diabetes market, particularly drivers and restraints
• Sales forecasts for major drugs and discussion of prominent companies’ activities
• Separate analyses and forecasts for the oral anti-diabetics and insulin analogues markets
• Regional analyses for the United States, Europe, Japan, China and India, all divided into sales forecasts for oral anti-diabetics and insulin analogues
• Expert opinion - derived from original research interviews - discussing diabetes research, promising drugs and the commercial and therapeutic significance of the obesity epidemic on diabetes incidence and treatment, present and future
• Analyses of crucial future trends, including ultra-long-acting drugs and novel insulin-delivery technologies, as well as more-radical developments.

• To receive forecasts of global revenue trends for diabetes treatments from 2009 to 2023
• To gain in-depth sales forecasts, from 2009 to 2023, covering strengths and weaknesses of key products and sub-markets
• To gain an understanding of all sectors of the diabetes market, including commercial analyses of individual drugs, drug classes, pipelines and regional markets
• To discover insight from original interviews with key opinion leaders (KOLs)
• To find out how the diabetes market is set to change dramatically over the next fifteen years
• To discover how the diabetes management sector is evolving worldwide in terms of diagnosis, assessment, treatment and patient compliance
• To discover exactly why diabetes is a major concern for governments, and why this serious chronic illness is one of the most important global healthcare issues, with hundreds of millions of people suffering from diabetes and hundreds of million more currently at risk

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.